DRREDDY:NSE:NSE-Dr. Reddy's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1352.65

Change

0.00 (0.00)%

Market Cap

USD 1,157.53B

Volume

1.57M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-156.65 (-2.59%)

USD 1,561.24B
MANKIND:NSE Mankind Pharma Ltd

-53.00 (-1.80%)

USD 1,185.39B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-39.90 (-1.17%)

USD 1,152.44B
LUPIN:NSE Lupin Limited

-8.55 (-0.36%)

USD 1,016.49B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-14.35 (-1.47%)

USD 978.76B
AUROPHARMA:NSE Aurobindo Pharma Limited

-6.65 (-0.50%)

USD 737.59B
ALKEM:NSE Alkem Laboratories Limited

+24.35 (+0.44%)

USD 665.89B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-12.35 (-0.75%)

USD 447.54B
IPCALAB:NSE IPCA Laboratories Limited

-16.00 (-0.92%)

USD 421.90B
AJANTPHARM:NSE Ajanta Pharma Limited

+73.50 (+2.56%)

USD 380.23B

ETFs Containing DRREDDY:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.19% 22% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.19% 22% F 20% F
Trailing 12 Months  
Capital Gain 15.90% 32% F 52% F
Dividend Return 3.43% 98% N/A 94% A
Total Return 19.32% 37% F 55% F
Trailing 5 Years  
Capital Gain 134.49% 24% F 37% F
Dividend Return 11.09% 84% B 62% D
Total Return 145.59% 26% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain 11.42% 18% F 19% F
Dividend Return 12.13% 19% F 20% F
Total Return 0.71% 66% D+ 53% F
Risk Return Profile  
Volatility (Standard Deviation) 24.34% 92% A 84% B
Risk Adjusted Return 49.81% 46% F 29% F
Market Capitalization 1,157.53B 97% N/A 96% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.